A symmetry result for cooperative elliptic systems with singularities

We obtain symmetry results for solutions of an elliptic system of equation possessing a cooperative structure. The domain in which the problem is set may possess "holes" or "small vacancies" (measured in terms of capacity) along which the solution may diverge. The method of proof relies on the moving plane technique, which needs to be suitably adapted here to take care of the complications arising from the vacancies in the domain and the analytic structure of the elliptic system

A symmetry result for cooperative elliptic systems with singularities

We obtain symmetry results for solutions of an elliptic system of equationpossessing a cooperative structure. The domain in which the problem is set maypossess "holes" or "small vacancies" (measured in terms of capacity) along which thesolution may diverge.The method of proof relies on the moving plane technique, which needs to besuitably adapted here to take care of the complications arising from the vacancies inthe domain and the analytic structure of the elliptic system

Semilinear elliptic equations involving mixed local and nonlocal operators

In this paper, we consider an elliptic operator obtained as the superposition of a classical second-order differential operator and a nonlocal operator of fractional type. Though the methods that we develop are quite general, for concreteness we focus on the case in which the operator takes the form $-\Delta+(-\Delta)^s$, with $s\in(0,1)$. We focus here on symmetry properties of the solutions and we prove a radial symmetry result, based on the moving plane method, and a one-dimensional symmetry result, related to a classical conjecture by G.W. Gibbons

Performability evaluation of the ERTMS/ETCS - Level 3

Abstract Level 3 of the ERTMS/ETCS improves the capacity of railways by replacing fixed-block signalling, which prevents a train to enter a block occupied by another train, with moving block signalling, which allows a train to proceed as long as it receives radio messages ensuring that the track ahead is clear of other trains. If messages are lost, a train must stop for safety reasons within a given deadline, even though the track ahead is clear, making the availability of the communication link crucial for successful operation. We combine analytic evaluation of failures due to burst noise and connection losses with numerical solution of a non-Markovian model representing also failures due to handovers between radio stations. In so doing, we show that handovers experienced by a pair of chasing trains periodically affect the availability of the radio link, making behavior of the overall communication system recurrent over the hyper-period of periodic message releases and periodic arrivals at cell borders. As a notable aspect, non-Markovian transient analysis within two hyper-periods is sufficient to derive an upper bound on the first-passage time distribution to an emergency brake, permitting to achieve a trade-off between railway throughput and stop probability. A sensitivity analysis is performed with respect to train speed and headway distance, permitting to gain insight into the consequences of system-level design choices

Multidimensional spectral analysis of the ultrasonic radiofrequency signal for characterization of media

AbstractThe importance of the analysis of the radiofrequency signal is by now recognized in the field of tissue characterization via ultrasound. The RF signal contains a wealth of information and structural details that are usually lost in the B-Mode representation. The HyperSPACE (Hyper SPectral Analysis for Characterization in Echography) algorithm presented by the authors in previous papers for clinical applications is based on the radiofrequency ultrasonic signal. The present work describes the method in detail and evaluates its performance in a repeatable and standardized manner, by using two test objects: a commercial test object that simulates the human parenchyma, and a laboratory-made test object consisting of human blood at different dilution values. In particular, the sensitivity and specificity in discriminating different density levels were estimated. In addition, the robustness of the algorithm with respect to the signal-to-noise ratio was also evaluated

svr 24 achievement two weeks after a tripled dose of daclatasvir in an hcv genotype 3 patient

Abstract Directly-acting antivirals (DAA) have changed the chronic hepatitis C virus (HCV) infection therapeutic scenario allowing virus eradication in more than 95% of patients, independently from the genotype, with 12 to 24-week treatment regimens. We describe a 51-year-old Pakistani man with a chronic HCV-genotype 3 (GT3a) infection with moderate liver fibrosis, who achieved sustained virological response (SVR) 24 after a tripled dose of Daclatasvir (DCV) taken erroneously associated to Sofosbuvir (SOF). The patient had a concomitant intestinal TB infection whose treatment had been delayed in order to firstly eradicate HCV to reduce the liver toxicity of anti-mycobacterial drugs. Thanks to the cultural mediator support, we explained to the patient the correct posology of each drug to take during the day consisting of 12 week SOF (400 mg daily) plus DCV (60 mg daily) regimen. He returned 13 days after for a programmed visit and we were surprised to learn that he had taken 3 pills of DCV (180 mg/daily) instead of one, thus ending DCV assumption after only 9 days while SOF was taken correctly. He complained no symptoms. We immediately performed blood test that showed alteration of lactate dehydrogenase, creatine phosphokinase, and creatin kinase MB activity. At day 15 we stopped SOF closely monitoring the patient. Blood test alterations returned normal after one week of treatment suspension, HCV viremia remained suppressed after 4, 12 and 24 weeks proving HCV eradication. If confirmed, these data could suggest that higher doses of DCV, if tolerated, might be employed in short-time HCV-GT3 treatment

Treatment of Graft versus Host Disease with Mesenchymal Stromal Cells: A Phase I Study on 40 Adult and Pediatric Patients

Abstract This phase I multicenter study was aimed at assessing the feasibility and safety of intravenous administration of third party bone marrow–derived mesenchymal stromal cells (MSC) expanded in platelet lysate in 40 patients (15 children and 25 adults), experiencing steroid-resistant grade II to IV graft-versus-host disease (GVHD). Patients received a median of 3 MSC infusions after having failed conventional immunosuppressive therapy. A median cell dose of 1.5 × 10 6 /kg per infusion was administered. No acute toxicity was reported. Overall, 86 adverse events and serious adverse events were reported in the study, most of which (72.1%) were of infectious nature. Overall response rate, measured at 28 days after the last MSC injection, was 67.5%, with 27.5% complete response. The latter was significantly more frequent in patients exhibiting grade II GVHD as compared with higher grades (61.5% versus 11.1%, P = .002) and was borderline significant in children as compared with adults (46.7 versus 16.0%, P = .065). Overall survival at 1 and 2 years from the first MSC administration was 50.0% and 38.6%, with a median survival time of 1.1 years. In conclusion, MSC can be safely administered on top of conventional immunosuppression for steroid resistant GVHD treatment. Eudract Number 2008-007869-23, NCT01764100